Last reviewed · How we verify
Sm-p80
At a glance
| Generic name | Sm-p80 |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site pain
- Fatigue
- Myalgia
- Headache
- Injection site swelling
- Malaise
- Vessel puncture site haemorrhage
- Arthralgia
- Chills
- Injection site pruritus
- COVID-19
- Upper respiratory tract infection
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar (PHASE1)
- Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults (PHASE1)
- Sm-p80 Schistosomiasis Challenge Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sm-p80 CI brief — competitive landscape report
- Sm-p80 updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI